Skip to main content

Immunomodulation for glioblastoma.

Publication ,  Journal Article
Reardon, DA; Wen, PY; Wucherpfennig, KW; Sampson, JH
Published in: Curr Opin Neurol
June 2017

PURPOSE OF REVIEW: Immunotherapy has emerged as a cornerstone of modern oncology with regulatory approvals for a variety of immunotherapeutics being achieved for a spectrum of cancer indications. Nonetheless the role of these approaches for patients with glioblastoma (GBM), the most common and deadliest primary malignant brain neoplasm, remains unknown. In this review, we summarize the current status of clinical development for the major types of immunotherapeutics, including vaccines, cell-based therapies, and immune checkpoint modulators for GBM. We also highlight potential challenges confronting the development of these agents. RECENT FINDINGS: Growing preclinical and clinical data is emerging regarding the potential of immunotherapy strategies for GBM. In parallel, growing data demonstrating that historical dogma classifying the brain as immunoprivileged is inaccurate but that many tumors, including GBM evoke myriad mechanisms to suppress antitumor immune responses. SUMMARY: Ongoing initial trials will provide preliminary data on the role of immunotherapy for GBM patients. Subsequent clinical development steps will likely require rationally designed combinatorial regimens.

Duke Scholars

Published In

Curr Opin Neurol

DOI

EISSN

1473-6551

Publication Date

June 2017

Volume

30

Issue

3

Start / End Page

361 / 369

Location

England

Related Subject Headings

  • Neurology & Neurosurgery
  • Immunotherapy
  • Immunomodulation
  • Humans
  • Glioblastoma
  • Cancer Vaccines
  • Brain Neoplasms
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1702 Cognitive Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Wen, P. Y., Wucherpfennig, K. W., & Sampson, J. H. (2017). Immunomodulation for glioblastoma. Curr Opin Neurol, 30(3), 361–369. https://doi.org/10.1097/WCO.0000000000000451
Reardon, David A., Patrick Y. Wen, Kai W. Wucherpfennig, and John H. Sampson. “Immunomodulation for glioblastoma.Curr Opin Neurol 30, no. 3 (June 2017): 361–69. https://doi.org/10.1097/WCO.0000000000000451.
Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH. Immunomodulation for glioblastoma. Curr Opin Neurol. 2017 Jun;30(3):361–9.
Reardon, David A., et al. “Immunomodulation for glioblastoma.Curr Opin Neurol, vol. 30, no. 3, June 2017, pp. 361–69. Pubmed, doi:10.1097/WCO.0000000000000451.
Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH. Immunomodulation for glioblastoma. Curr Opin Neurol. 2017 Jun;30(3):361–369.

Published In

Curr Opin Neurol

DOI

EISSN

1473-6551

Publication Date

June 2017

Volume

30

Issue

3

Start / End Page

361 / 369

Location

England

Related Subject Headings

  • Neurology & Neurosurgery
  • Immunotherapy
  • Immunomodulation
  • Humans
  • Glioblastoma
  • Cancer Vaccines
  • Brain Neoplasms
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1702 Cognitive Sciences